Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies

International Journal of Clinical Practice

Volumn 58, Issue 5, 2004, Pages 511-516

  Nadal, Elisabet ^a   Olavarria, E ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

CML; Glivec; Imatinib; STI

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; BCR ABL PROTEIN; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DIURETIC AGENT; ERYTHROMYCIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; PARACETAMOL; PEGINTERFERON; PHENYTOIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYRROLE DERIVATIVE; RIFAMPICIN; SIMVASTATIN; STEM CELL FACTOR RECEPTOR; STEROID;

AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MILK LEVEL; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; EYELID EDEMA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HUMAN; HYPEREOSINOPHILIC SYNDROME; LIVER TOXICITY; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIDE EFFECT; TERATOGENICITY; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASMS; PILOT PROJECTS; PIPERAZINES; PROGNOSIS; PYRIMIDINES;

EID: 2942716849     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00173.x     Document Type: Article

References (47)

1. Sawyers CL. Chronic myeloid leukaemia. N Engl J Med 1999; 340: 1330-40.
2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukaemia. Blood 2000; 96: 3343-56.
3. Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94: 1517-36.
4. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039-42.
5. Bonifazi F, de Vivo A, Rosti G et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood 2001; 98: 3074-81.
6. Guilhot F, Chastang C, Michallet M et al. Interferon α-2b combined with cytarabine versus interferon alone in chronic myelogenous leukaemia. N Engl J Med 1997; 337: 223-9.
7. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087-92.
8. Wadhwa J, Szydlo RM, Apperley JF et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukaemia. Blood 2002; 99: 2304-9.
9. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-4.
10. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-8.
11. Carroll M, Ohno-Jones S, Tamura S et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90: 4947-52.
12. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3-7.
13. Peng B, Hayes M, Druker B et al. Clinical pharmacokinetics and pharmacodynamics of STI571 in a phase I trial in chronic myelogenous leukemia (CML) patients. Proc Am Assoc Cancer Res 2000; 41: 544 [Abstract].
14. Novartis Pharmaceuticals Corporation. Gleevec (imatinib mesylate) capsules prescribing information. East Hanover, (NJ) 2001.
15. Petzer AL, Gunsilius E, Hayes M et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002; 117: 623-5.
16. Druker BJ, Talpaz M, Debra J et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001; 344: 1031-7.
17. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
18. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-52.
19. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-37.
20. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-9.
21. Kantarjian HM, Cortes J, O'Brien S et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547-53.
22. O'Brien S, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med 2003; 348: 994-1004.
23. Hsiao LT, Chung HM, Lin JT et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002; 117: 620-2.
24. Savage DG, Antman KH. Imatinib mesylate- A new oral targeted therapy. N Engl J Med 2002; 346: 683-93.
25. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 2002; 20: 325-34.
26. Kartajan H, Sawyers CH, Hochhaus A et al. Hematologic and cytogenetic responses to Imatinib Mesylate in chronic myeologenous leukaemia. N Engl J Med 2002; 346: 645-52.
27. Marin D, Bua M, Marktel S et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with Imatinib Mesylate after failure of interferon alpha. Leukemia 2003; 17 (8): 1448-53.
28. Cervantes F, Hernández-Boluda JC, Steegmann JL et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progressiom-free survival in 150 patients. Haematologica 2003; 88: 117-1122.
29. Mahon FX, Deininger MW, Schultheis B et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-9.
30. Gambacorti-Passerini C, Barni R, le Coutre P et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641-50.
31. Kantarjian HM, Talpaz M, O'Brien S et al. Dose escalation of Imatinib Mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukaemia. Blood 2003; 101: 473-5.
32. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood 2000; 96: 3195-9.
33. Kano Y, Akutsu M, Tsunoda S et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97: 1999-2007.
34. Marley SB, Davidson RJ, Goldman JM, Gordon MY. Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. Br J Haematol 2002; 116: 162-5.
35. Peters DG, Hoover RR, Gerlach MJ et al. Activity of the famesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001; 97: 1404-12.
36. Thomas DA, Cortes J, Giles FJ et al. Combination of Hyper-CVAD with imatinib mesylate (STI571) for Philadelphia (Ph)-positive adult acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia in lymphoid blast phase (CML-LBP). Blood 2001; 98: 803a [Abstract].
37. Olavarria E, Craddock C, Dazzi F et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002; 99: 3861-2.
38. Kantarjian HM, O'Brien S, Cortes J et al. Imatinib mesylate patients for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100 (5): 1590-5.
39. O'Brien S, Vieira S, Connors S et al. Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t (9;12) translocation. Blood 2002; 99: 3465-7.
40. Apperley JF, Gardembas M, Melo JV et al. Response to Imatinib Mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347 (7): 481-7.
41. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE. Molecular evidence for cfficacy of STI-571 in chronic myelomonocytic leukaemia (CMML) with a platelet-derived growth factor β-receptor (PDGFβR) fiision oncogene. Blood 2001; 98: 631a [Abstract].
42. Ma Y, Zeng S, Metcalfe DD et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741-4.
43. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577-8.
44. Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of Imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348 (13): 1201-14.
45. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6.
46. van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-3.
47. Blanke CD, von Mehren M, Joensuu H et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-kit (CD117). Prog Proc Am Soc Clin Oncol 2001; 20: 1a [Abstract].